WT1A peptide vaccination trials in AML and MDS patients have found that WT1A-specific CD8+ T-cell responses are short-lived and expand poorly following in vitro culture or repeated vaccination.19, 20 In addition, it is very difficult to directly compare the de novo efficacy of different vaccine formulations within the same individual. Here, CD8A is linked to myelodysplastic syndrome.